Resonant Clinical Solutions expands European advanced therapy and cryogenic storage capabilities via Creapharm Bioservices acquisition
Executive summary: Resonant Clinical Solutions announced the acquisition of Creapharm Bioservices to bolster its advanced therapy and cryogenic storage services in Europe. The transaction expands Resonant’s capacity to store and handle cell and gene therapy products, addressing rising demand for specialized biostorage and logistics in the ATMP market.
Who is involved: Resonant Clinical Solutions (US‑based), Creapharm Bioservices (European cryogenic storage provider), and the PR Newswire distribution service.
Likely next: Integration of Creapharm’s storage sites into Resonant’s network is expected, with potential cross‑selling of services to existing clients and further M&A activity in the European advanced therapy supply chain.
Resonant Clinical Solutions announced on September 6, 2026 the purchase of Creapharm Bioservices, a provider of cryogenic storage and specialized logistics for advanced therapies. The acquisition adds Creapharm’s European facilities to Resonant’s global biorepository network, expanding the company’s capacity to support complex cell and gene therapy programs. Financial terms of the deal were not disclosed in the press release. The move reflects growing demand for integrated storage and logistics solutions within the ATMP sector.
Timeline
- — Resonant Clinical Solutions renforce ses capacités de thérapies de pointe et de stockage cryogénique grâce à l'acquisition de Creapharm Bioservices (PR Newswire)
- — Resonant Clinical Solutions erweitert mit der Übernahme von Creapharm Bioservices seine Kapazitaten fur innovative Therapien und kryogene Lagerung (PR Newswire)
Analysis — what this means
Sectors affected
- Advanced therapy manufacturing
- Cryogenic storage and logistics
- Cell and gene therapy clinical trials
Regulatory implications
- Must comply with EU Directive 2004/23/EC on quality and safety of human tissues and cells
- Must adhere to EU GDPR requirements for processing patient‑derived sample data
Historical parallels
- Thermo Fisher Scientific’s acquisition of Patheon in 2017 to expand biologics services
- Charles River Laboratories’ acquisition of Cognate BioServices in 2021 for cell therapy manufacturing
Key entities
Sources
Open the full interactive case file on Beyond →